Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Frank E.H.P. van Baarle"'
1
Coronavirus disease 2019 is associated with catheter-related thrombosis in critically ill patients: A multicenter case-control study
Autor: Alexander P.J. Vlaar, Pieter R. Tuinman, Jasper M. Smit, David J. van Westerloo, Frederikus A. Klok, Kee F. Choi, Jorge E. Lopez Matta, Roel Vink, Menno V. Huisman, Carlos V. Elzo Kraemer, Armand R. J. Girbes, Marcella C.A. Müller, Frank E.H.P. van Baarle
Publikováno v: Thrombosis Research
Thrombosis Research, 200, 87-90. Elsevier Limited
Smit, J M, Lopez Matta, J E, Vink, R, Müller, M C A, Choi, K F, van Baarle, F E H P, Vlaar, A P J, Klok, F A, Huisman, M V, Elzo Kraemer, C V, Girbes, A R J, Van Westerloo, D J & Tuinman, P R 2021, ' Coronavirus disease 2019 is associated with catheter-related thrombosis in critically ill patients : A multicenter case-control study ', Thrombosis Research, vol. 200, pp. 87-90 . https://doi.org/10.1016/j.thromres.2021.01.013
Thrombosis research, 200, 87-90. Elsevier Limited
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a192eba3854f595a096d554fb6661809
https://doi.org/10.1016/j.thromres.2021.01.013
Zobrazit plný text záznamu
2
High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages
Autor: Korneliusz Golebski, Federica Linty, Harm Jan Bogaard, Guillermo R. Griffith, Godelieve J. de Bree, Marit J. van Gils, Willianne Hoepel, Tom G. Caniels, Lynn Mes, Hung-Jen Chen, Frank E.H.P. van Baarle, Cornelis M. van Drunen, René E. Jonkers, Jurjan Aman, Sona Allahverdiyeva, Menno P.J. de Winther, Jeroen den Dunnen, Karlijn van der Straten, Manfred Wuhrer, Mads Delbo Larsen, Gestur Vidarsson, Jan Nouta, Rogier W. Sanders, Theo Rispens, Alexander P.J. Vlaar, Maurice Steenhuis, Gertjan Wolbink, Diederik van de Beek, Philip J. M. Brouwer, Xue D. Manz, Cindy P. A. A. van Roomen, Peter I. Bonta, Chiara Elisabeth Geyer, Annette E. Neele, Lisa Willemsen, Steven W. de Taeye
Publikováno v: Science Translational Medicine, 13(596):eabf8654. American Association for the Advancement of Science
Hoepel, W, Chen, H-J, Geyer, C E, Allahverdiyeva, S, Manz, X D, de Taeye, S W, Aman, J, Mes, L, Steenhuis, M, Griffith, G R, Bonta, P I, Brouwer, P J M, Caniels, T G, van der Straten, K, Golebski, K, Jonkers, R E, Larsen, M D, Linty, F, Nouta, J, van Roomen, C P A A, van Baarle, F E H P, van Drunen, C M, Wolbink, G, Vlaar, A P J, de Bree, G J, Sanders, R W, Willemsen, L, Neele, A E, van de Beek, D, Rispens, T, Wuhrer, M, Bogaard, H J, van Gils, M J, Vidarsson, G, de Winther, M & den Dunnen, J 2021, ' High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages ', Science Translational Medicine, vol. 13, no. 596, eabf8654 . https://doi.org/10.1126/scitranslmed.abf8654
Science Translational Medicine
Science Translational Medicine, 13(596). AMER ASSOC ADVANCEMENT SCIENCE
Science translational medicine, 13(596):eabf8654. American Association for the Advancement of Science
High titers and low fucosylation of human anti-spike protein IgG promote alveolar macrophage activation and inflammation.
Patients diagnosed with coronavirus disease 2019 (COVID-19) become critically ill primarily around the time of activation o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3776bc2b7ca6cf18e6e8c677efa6c2a
https://research.vumc.nl/en/publications/9c41a896-d9c0-4ca8-a875-c845ffd899e8
Zobrazit plný text záznamu
3
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Autor: Leo M. A. Heunks, Frank E.H.P. van Baarle, Lieuwe D. J. Bos, Frederique Paulus, Esther B. Bulle, Simon Rueckinger, Marcus J. Schultz, Matthijs C. Brouwer, Pieter van Paassen, Janneke Horn, Martin Witzenrath, Ingeborg E. van Zeggeren, E. Marleen Kemper, W. Joost Wiersinga, Marcel C. G. van de Poll, Sjoerd A.M.E.G. Timmermans, Rutger Koning, Korinna Pilz, Niels C. Riedemann, Alexander P.J. Vlaar, Diederik van de Beek, Iwan C. C. van der Horst, Matthias Busch, Sanne de Bruin, Liora ter Horst, Ren Feng Guo
Publikováno v: The Lancet Rheumatology, 2(12), e764-e773. Lancet Publishing Group
The Lancet Rheumatology, 2(12), E764-E773. Lancet Publishing Group
Vlaar, A P J, de Bruin, S, Busch, M, Timmermans, S A M E G, van Zeggeren, I E, Koning, R, Ter Horst, L, Bulle, E B, van Baarle, F E H P, van de Poll, M C G, Kemper, E M, van der Horst, I C C, Schultz, M J, Horn, J, Paulus, F, Bos, L D, Wiersinga, W J, Witzenrath, M, Rueckinger, S, Pilz, K, Brouwer, M C, Guo, R-F, Heunks, L, van Paassen, P, Riedemann, N C & van de Beek, D 2020, ' Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO) : an exploratory, open-label, phase 2 randomised controlled trial ', The Lancet Rheumatology, vol. 2, no. 12, pp. e764-e773 . https://doi.org/10.1016/S2665-9913(20)30341-6
The Lancet Rheumatology
Background Severe COVID-19 is characterised by inflammation and coagulation in the presence of complement system activation. We aimed to explore the potential benefit and safety of selectively blocking the anaphylatoxin and complement protein C5a wit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7a3cabed40314643ba9bb8842abe17e
https://pure.amc.nl/en/publications/antic5a-antibody-ifx1-vilobelimab-treatment-versus-best-supportive-care-for-patients-with-severe-covid19-panamo(1f96aacf-dec4-4976-90c4-4807fe469d43).html
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje